Sysmex Europe SE has signed a multi-market EMEA distribution agreement with Cerca Biotech, the company behind the innovative breast cancer diagnostic assay – MammaTyper®. As a result of the agreement, MammaTyper® will become part of the Sysmex Life Science portfolio in 13 territories across EMEA, including the UK, Ireland and the majority of mainland Europe.
MammaTyper® is the first real innovation in subtyping breast cancer in decades. Using RT-qPCR technology proven during the COVID-19 pandemic, the multigene test works through an easily replicated and quantitative measurement of marker gene expression, classifying each sample as a St. Gallen molecular subtype. MammaTyper® provides standardised, objective results and can also accurately assess HER2-low tumours and Ki-67 markers, offering a reliable basis for selecting the best treatment option for patients.
By being robustly reproducible, it avoids many of the common pre-analytical errors in the pathology laboratory, especially for the proliferation marker Ki-67 – critical in luminal subtyping and prognosis. Using MammaTyper® to subtype breast cancer tissue is a valuable resource for pathologists and can provide the reassurance with accurate subtyping for tailored treatment which are patient-specific.
By sharing deep scientific knowledge and an understanding of clinical needs, Sysmex Life Science and Cerca Biotech will work closely together to enable individualised breast cancer diagnostics across many markets.
Richard Hughes, Director at Cerca Biotech:
“Repeatable, reproducible testing is the only way we can ensure that every person diagnosed with breast cancer can access the best treatment for their individual case. Through this partnership with Sysmex Europe, MammaTyper® will be available as a valuable diagnostic tool to more pathologists in more markets across Europe. We are proud that MammaTyper® will be part of Sysmex’s cutting-edge portfolio.”
Samantha Giangregorio, Head of Life Science, Vice President Sysmex Europe SE:
“We are excited to be collaborating with Cerca Biotech and to extend and strengthen our innovative molecular portfolio, building on the success of our OSNA® solution in breast cancer. Considering the clinical need for accurate and individualised diagnostics, the MammaTyper® can play a key role in the breast cancer diagnostic pathway, providing guidance for the right treatment, thus improving the quality of life of patients.”
About Cerca Biotech
Recent research studies undertaken in the UK, Portugal and China concluded that MammaTyper® could provide a reliable, efficient, and reproducible alternative to the molecular subtyping of breast cancer tumours. For more details on these studies, please see www.cercabiotech.com/news
MammaTyper® is part of Cerca Biotech, a German-based diagnostic company focused on bringing innovative solutions to the oncology and women’s health market. Cerca Biotech strives to introduce the best tests to meet clinical needs at an affordable cost, with clinical accuracy and rapid results at the core. For more information, please visit www.cercabiotech.com
About Sysmex Europe SE
Sysmex supports healthcare professionals around the world in lighting the way with diagnostics by providing a broad range of medical diagnostics products and solutions. In the fields of haematology, urinalysis, haemostasis, life science, flow cytometry, essential healthcare and immunochemistry, we combine highly dependable, multi-functional and easy-to-operate instruments, a variety of reagents and software, plus reliable service and support.
Sysmex Europe SE, located near Hamburg, Germany, is a subsidiary of the Sysmex Corporation from Kobe, Japan. From our Hamburg offices, we serve our affiliates, distributors and customers throughout Europe, the Middle East, and Africa (EMEA). For more information, visit www.sysmex-europe.com.